* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download A comprehensive platform for T cell Stimulation based on
DNA vaccination wikipedia , lookup
Lymphopoiesis wikipedia , lookup
Monoclonal antibody wikipedia , lookup
Duffy antigen system wikipedia , lookup
Innate immune system wikipedia , lookup
Immunosuppressive drug wikipedia , lookup
Adaptive immune system wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
Molecular mimicry wikipedia , lookup
Modular biomaterials for immunotherapy and diagnostics: Carriers for Drug and Antigen Delivery to Immune Cells Tarek Fahmy Yale University Dept. of Biomedical and Chemical Engineering Immunoengineering www.fahmylab.org APC’s present antigen and create a stimulatory or inhibitory microenvironment for T cell stimulation Virus or Bacteria Tumor Cells Antigen Processing DC B cell Antigen-presenting cell (Uptake of Pathogen) Antigen Display to T cells in lymph nodes Peptide/MHC CD4+ T cell DC CD8+ T cell CD8+ T cell CD8+ T cell Activated T Cells T cells circulate through body TCR CD8+ T cell Examples of what we Do... Interface of Materials science and Immunology 1. Pathogen-associated molecular patterns (PAMPS) on nanocarriers: a paradigm for engineering new vaccines. 2. Artificial antigen-presenting cells for adoptive therapy based on IL-2 loaded biodegradable carriers. 3. Breaking Tumor immuno-inhibition. Nanocarrier –mediated combinatorial delivery. 4. Directed Delivery for autoimmunity and transplant rejection PAMPS on Nanoparticles: An old idea... New Formulation for vaccines West Nile ~40-70 nm DC Gram-negative bacteria HIV ~100 nm ~1000 nm Pathogen-Recognition Receptors Example: Toll-Like Receptors (TLRs) Nanoparticle Vaccine Vector: PAMP on the outside. Antigen on the inside. Antigen PAMP Pathogen Pathogen-Associated Molecular Patterns (PAMP) Ex: Flagellin, LPS, CpG Artificial Antigen presenting cells for adoptve immunotherapy. Adoptive immunotherapy IL-2 April 2010: Dendreon Makes History: FDA Approves First Active Immune-Booster to Fight Cancer. Provenge® Dendreon Sets Provenge Price at $93,000, Says Only 2,000 People Will Get it in First Year The tumor microenvironment is immunoinhibitory. Solution: Combination Delivery www.fahmylab.org Postdocs Fiona Sharp Ragy Ragheb Michael Look Former: Arunima Banerjee Dongin Kim Former: Eric Stern Collaborators Mark Reed (Nanosensors) Grad Students Former: Jason Criscione Former: Stacey Demento Former: Tarek Fadel Former: Michael Look Former: Erin Steenblock Former: Jason Park Enping Hong Alyssa Siefert Michael McHugh Sean Bickerton Shihan Khan Su Metcalfe (Parkinsons) Priti Kumar(HIV) Michael Caplan (Vaccines) Mark Saltzman (Biomaterials) Richard Flavell (Cancer) Kevan Herold (Diabetes) Chris Hunter (Parasitic infections) Daniel Goldstein (Transplantation) Albert Sinusas (CT/SPECT imaging) Diane McMahon-Pratt (Leshmaniasis) Choukri Ben Mamoun (Malaria) Leiping Chen (Cancer) Jay Chen (Radiology)